•COVID-19salesdecreasedbyCHF-0.8bnandLOE1impactwasCHF-0.6bn,bothinlinewithguidance(atCER) •CoreOPincreasedby+11%,GroupcoreOPmarginup+1.9%p,CoreEPSgrowth+9%,OperatingFreeCashFlowof+9%atCHF8.4bn(allatCER) KeymilestonesachievedinQ2 •Pharmaregulatory:EUapprovalOcrevusSCinRMS/PPMSandAlecensainad...